{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:55:32Z","timestamp":1793328932209,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.eururo.2024.01.012","type":"journal-article","created":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T15:32:53Z","timestamp":1706542373000},"page":"52-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Impact of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-8511","authenticated-orcid":false,"given":"Wesley R.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiara M.","family":"Booker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan R.","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevyn J.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Czernin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8839-4379","authenticated-orcid":false,"given":"Jeremie","family":"Calais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.01.012_b0005","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.291.11.1325","article-title":"Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy","volume":"291","author":"Stephenson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2024.01.012_b0010","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2016.06.046","article-title":"Clinical outcomes for patients with Gleason score 9\u201310 prostate adenocarcinoma treated with radiotherapy or radical prostatectomy: a multi-institutional comparative analysis","volume":"71","author":"Kishan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.01.012_b0015","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.01.012_b0020","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.01.012_b0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.01.012_b0030","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0035","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2014.58.8525","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement","volume":"32","author":"Freedland","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","article-title":"Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy","volume":"61","author":"Kane","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.01.012_b0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2214\/AJR.19.21836","article-title":"Prognostic value of pretreatment MRI in patients with prostate cancer treated with radiation therapy: a systematic review and meta-analysis","volume":"214","author":"Woo","year":"2020","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.eururo.2024.01.012_b0050","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0055","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0060","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.01.012_b0070","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.01.012_b0075","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.radonc.2008.05.006","article-title":"Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group","volume":"88","author":"Sidhom","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.radonc.2007.07.017","article-title":"Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group","volume":"84","author":"Poortmans","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0085","article-title":"ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer","volume":"41","author":"Dal Pra","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0090","unstructured":"National Comprehensive Cancer Network. Prostate cancer 1.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.eururo.2024.01.012_b0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.121.263262","article-title":"Appropriate use criteria for prostate-specific membrane antigen PET imaging","volume":"63","author":"Jadvar","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.01.012_b0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0105","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.122.264743","article-title":"Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study","volume":"64","author":"Olivier","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.01.012_b0110","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"(68)Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.01.012_b0115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2967\/jnumed.117.196444","article-title":"The utility of PET\/CT in the planning of external radiation therapy for prostate cancer","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.01.012_b0120","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-021-00497-7","article-title":"Salvage therapy for prostate cancer after radical prostatectomy","volume":"18","author":"Zaorsky","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2024.01.012_b0125","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2967\/jnumed.122.265025","article-title":"PSMA PET\/CT-based atlas for prostatic bed recurrence after radical prostatectomy: clinical implications for salvage radiation therapy contouring guidelines","volume":"64","author":"Sonni","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.01.012_b0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12885-018-5200-1","article-title":"Randomized prospective phase III trial of (68)Ga-PSMA-11 PET\/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]","volume":"19","author":"Calais","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2024.01.012_b0135","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.01.012_b0140","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0145","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year freedom from progression after (68)Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2024.01.012_b0150","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","article-title":"Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial","volume":"7","author":"Hope","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.01.012_b0155","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"(18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1016\/j.eururo.2024.10.022","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824000137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824000137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T11:27:02Z","timestamp":1736854022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824000137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0302283824000137"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.01.012","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}